Download PDF
Semin Thromb Hemost 2023; 49(03): 284-294
DOI: 10.1055/s-0042-1758059
Review Article

From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease

Adriana Inés Woods 
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET-Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
,
Juvenal Paiva 
2   Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
,
Celia Dos Santos 
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET-Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
,
María Fabiana Alberto 
2   Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
,
Analía Sánchez-Luceros 
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET-Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
2   Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires, CABA, Argentina
› Author Affiliations Funding Our work is supported by CONICET, Fundación Rene Barón, and Academia Nacional de Medicina (Buenos Aires), Argentina.
› Further Information
    Permissions and Reprints

Abstract

ADAMTS13 (a disintegrin-like metalloprotease domain with thrombospondin type 1 motif, member 13) is a protease of crucial importance in the regulation of the size of von Willebrand factor multimers. Very low ADAMTS13 activity levels result in thrombotic thrombocytopenic purpura, a rare and life-threatening disease. The mechanisms involved can either be acquired (immune-mediated thrombotic thrombocytopenic purpura [iTTP]) or congenital (cTTP, Upshaw–Schulman syndrome) caused by the autosomal recessive inheritance of disease-causing variants (DCVs) located along the ADAMTS13 gene, which is located in chromosome 9q34. Apart from its role in TTP, and as a regulator of microthrombosis, ADAMTS13 has begun to be identified as a prognostic and/or diagnostic marker of other diseases, such as those related to inflammatory processes, liver damage, metastasis of malignancies, sepsis, and different disorders related to angiogenesis. Since its first description almost 100 years ago, the improvement of laboratory tests and the description of novel DCVs along the ADAMTS13 gene have contributed to a better and faster diagnosis of patients under critical conditions. The ability of ADAMTS13 to dissolve platelet aggregates in vitro and its antithrombotic properties makes recombinant human ADAMTS13 treatment a potential therapeutic approach targeting not only patients with cTTP but also other medical conditions.

Keywords

ADAMTS13 - thrombotic thrombocytopenic purpura - Upshaw–Schulman syndrome - genotypic studies - phenotypic studies


Publication History

Article published online:
11 November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am 2017; 31 (06) 1081-1103
    CrossrefPubMedGoogle Scholar
  • 2 Dos Santos C, Paiva J, Romero ML. et al. Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina. eJHaem 2021; 2 (02) 149-156
    CrossrefPubMedGoogle Scholar
  • 3 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-24
    PubMedGoogle Scholar
  • 4 Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood 1947; 2 (06) 542-554
    PubMedGoogle Scholar
  • 5 Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16: 943-957
    CrossrefPubMedGoogle Scholar
  • 6 Upshaw Jr JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298 (24) 1350-1352
    CrossrefPubMedGoogle Scholar
  • 7 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-159
    CrossrefPubMedGoogle Scholar
  • 8 Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50 (03) 413-417
    CrossrefPubMedGoogle Scholar
  • 9 Rock GA, Shumak KH, Buskard NA. et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325 (06) 393-397
    CrossrefPubMedGoogle Scholar
  • 10 Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325 (06) 398-403
    CrossrefPubMedGoogle Scholar
  • 11 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 12 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
    CrossrefPubMedGoogle Scholar
  • 13 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
    CrossrefPubMedGoogle Scholar
  • 14 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339 (22) 1578-1584
    CrossrefPubMedGoogle Scholar
  • 15 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 16 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855): 488-494
    CrossrefPubMedGoogle Scholar
  • 17 Mariotte E, Azoulay E, Galicier L. et al; French Reference Center for Thrombotic Microangiopathies. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016; 3 (05) e237-e245
    CrossrefPubMedGoogle Scholar
  • 18 Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med 2021; 10 (03) 536-560
    CrossrefPubMedGoogle Scholar
  • 19 Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129 (21) 2836-2846
    CrossrefPubMedGoogle Scholar
  • 20 Rogers HJ, Allen C, Lichtin AE. Thrombotic thrombocytopenic purpura: the role of ADAMTS13. Cleve Clin J Med 2016; 83 (08) 597-603
    CrossrefPubMedGoogle Scholar
  • 21 Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7 (10) 1703-1710
    CrossrefPubMedGoogle Scholar
  • 22 Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60 (10) 1676-1682
    CrossrefPubMedGoogle Scholar
  • 23 Zhao T, Fan S, Sun L. The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome. BMC Genom Data 2021; 22 (01) 50
    CrossrefPubMedGoogle Scholar
  • 24 Tarasco E, Bütikofer L, Friedman KD. et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood 2021; 137 (25) 3563-3575
    CrossrefPubMedGoogle Scholar
  • 25 Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99 (18) 11902-11907
    CrossrefPubMedGoogle Scholar
  • 26 Fujimura Y, Matsumoto M, Isonishi A. et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl. 01) 283-301
    CrossrefPubMedGoogle Scholar
  • 27 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91 (01) 1-19
    CrossrefPubMedGoogle Scholar
  • 28 Scully M, Hunt BJ, Benjamin S. et al; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158 (03) 323-335
    CrossrefPubMedGoogle Scholar
  • 29 Matsumoto M, Fujimura Y, Wada H. et al; For TTP Group of Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour, and Welfare Sciences Research Grants. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol 2017; 106 (01) 3-15
    CrossrefPubMedGoogle Scholar
  • 30 Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion 2010; 50 (08) 1654-1664
    CrossrefPubMedGoogle Scholar
  • 31 Coppo P, Schwarzinger M, Buffet M. et al; French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5 (04) e10208
    CrossrefPubMedGoogle Scholar
  • 32 Bendapudi PK, Hurwitz S, Fry A. et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017; 4 (04) e157-e164
    CrossrefPubMedGoogle Scholar
  • 33 Zheng XL, Vesely SK, Cataland SR. et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18 (10) 2496-2502
    CrossrefPubMedGoogle Scholar
  • 34 Upadhyay VA, Geisler BP, Sun L. et al. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. Br J Haematol 2019; 186 (03) 490-498
    CrossrefPubMedGoogle Scholar
  • 35 Liu A, Dhaliwal N, Upreti H. et al. Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion 2021; 61 (01) 266-273
    CrossrefPubMedGoogle Scholar
  • 36 Fage N, Orvain C, Henry N. et al. Proteinuria increases the PLASMIC and French scores performance to predict thrombotic thrombocytopenic purpura in patients with thrombotic microangiopathy syndrome. Kidney Int Rep 2021; 7 (02) 221-231
    CrossrefPubMedGoogle Scholar
  • 37 Camilleri RS, Scully M, Thomas M. et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10 (09) 1792-1801
    CrossrefPubMedGoogle Scholar
  • 38 Jian C, Xiao J, Gong L. et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119 (16) 3836-3843
    CrossrefPubMedGoogle Scholar
  • 39 Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010; 91 (01) 20-29
    CrossrefPubMedGoogle Scholar
  • 40 Suzuki M, Murata M, Matsubara Y. et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313 (01) 212-216
    CrossrefPubMedGoogle Scholar
  • 41 Manea M, Kristoffersson A, Schneppenheim R. et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138 (05) 651-662
    CrossrefPubMedGoogle Scholar
  • 42 Majerus EM, Zheng X, Tuley EA, Sadler JE. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003; 278 (47) 46643-46648
    CrossrefPubMedGoogle Scholar
  • 43 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (06) 1662-1666
    CrossrefPubMedGoogle Scholar
  • 44 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (09) 2730-2735
    CrossrefPubMedGoogle Scholar
  • 45 Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82 (05) 1386-1389
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82 (05) 1382-1385
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83 (08) 2171-2179
    CrossrefPubMedGoogle Scholar
  • 48 Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002; 81 (08) 430-435
    CrossrefPubMedGoogle Scholar
  • 49 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
    CrossrefPubMedGoogle Scholar
  • 50 Muia J, Gao W, Haberichter SL. et al. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11 (08) 1511-1518
    CrossrefPubMedGoogle Scholar
  • 51 Favresse J, Lardinois B, Chatelain B, Jacqmin H, Mullier F. Evaluation of the fully automated HemosIL Acustar ADAMTS13 activity assay. Thromb Haemost 2018; 118 (05) 942-944
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Favaloro EJ, Mohammed S, Chapman K. et al. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost 2021; 19 (02) 417-428
    CrossrefPubMedGoogle Scholar
  • 53 Moore GW, Meijer D, Griffiths M. et al. A multi-center evaluation of TECHNOSCREEN® ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13. J Thromb Haemost 2020; 18 (07) 1686-1694
    CrossrefPubMedGoogle Scholar
  • 54 Bettoni G, Palla R, Valsecchi C. et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10 (08) 1556-1565
    CrossrefPubMedGoogle Scholar
  • 55 Lotta LA, Valsecchi C, Pontiggia S. et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost 2014; 12 (03) 329-336
    CrossrefPubMedGoogle Scholar
  • 56 Mancini I, Ferrari B, Valsecchi C. et al; Italian Group of TTP Investigators. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. Eur J Intern Med 2017; 39: 79-83
    CrossrefPubMedGoogle Scholar
  • 57 Kempfer AC, Paiva J, Sanchez-Luceros A. et al. Relationship between ADAMTS13 antigen (Ag) and free IgG anti-ADAMTS13 antibody (free IgG ab), functional ADAMTS13 inhibitor (FI) and circulating immune complexes (CIC) using two ELISA techniques, in patients (P) with acquired thrombotic thrombocytopenic purpura (aTTP). [abstract PB 710] Res Pract Thromb Haemost 2017; 1 (S1): 1300
    PubMedGoogle Scholar
  • 58 Mackie I, Mancini I, Muia J. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol 2020; 42 (06) 685-696
    CrossrefPubMedGoogle Scholar
  • 59 Meyer SC, Sulzer I, Lämmle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5 (04) 866-867
    CrossrefPubMedGoogle Scholar
  • 60 Zhou Z, Han H, Cruz MA, López JA, Dong JF, Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009; 101 (06) 1070-1077
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Muia J, Zhu J, Gupta G. et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111 (52) 18584-18589
    CrossrefPubMedGoogle Scholar
  • 62 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
    CrossrefPubMedGoogle Scholar
  • 63 Rim JH, Choi YJ, Gee HY. Genomic landscape and mutational spectrum of ADAMTS family genes in Mendelian disorders based on gene evidence review for variant interpretation. Biomolecules 2020; 10 (03) 449
    CrossrefPubMedGoogle Scholar
  • 64 Jiang Y, Huang D, Kondo Y. et al. Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13. J Cell Mol Med 2020; 24 (07) 4356-4361
    CrossrefPubMedGoogle Scholar
  • 65 Plaimauer B, Fuhrmann J, Mohr G. et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107 (01) 118-125
    CrossrefPubMedGoogle Scholar
  • 66 Kempfer AC, Powazniak Y, Calderazzo JC. et al. Human umbilical vein endothelial cells, platelets and human tumor cell lines express isoforms 2 and 3 of ADAMTS13 [abstract PB 3.33–3]. J Thromb Haemost 2013; 11 (S 2): 790
    PubMedGoogle Scholar
  • 67 Paiva J, Kempfer AC, Alberto MF. et al. mRNA Identification of a novel isoform (ISF) and ISF3 from ADAMTS13 in different types of cells. [abstract PB696] Res Pract Thromb Haemost 2017; 1 (S1): 1300
    PubMedGoogle Scholar
  • 68 Shomron N, Hamasaki-Katagiri N, Hunt R. et al. A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thromb Haemost 2010; 104 (03) 531-535
    PubMedGoogle Scholar
  • 69 Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 292-299
    CrossrefPubMedGoogle Scholar
  • 70 Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 2003; 29 (05) 479-488
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Harrison HN. Thrombotic thrombocytopenic purpura occurring in the puerperium; associated pancreatic islet-cell necrosis. AMA Arch Intern Med 1958; 102 (01) 124-130
    CrossrefPubMedGoogle Scholar
  • 72 May Jr HV, Harbert Jr GM, Thornton Jr WN. Thrombotic thrombocytopenic purpura associated with pregnancy. Am J Obstet Gynecol 1976; 126 (04) 452-458
    CrossrefPubMedGoogle Scholar
  • 73 Calderazzo JC, Kempfer A, Powazniak Y. et al. A new ADAMTS13 missense mutation (D1362V) in thrombotic thrombocytopenic purpura diagnosed during pregnancy. Thromb Haemost 2012; 108 (02) 401-403
    PubMedGoogle Scholar
  • 74 Moatti-Cohen M, Garrec C, Wolf M. et al; French Reference Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119 (24) 5888-5897
    CrossrefPubMedGoogle Scholar
  • 75 Sánchez-Luceros A, Farías CE, Amaral MM. et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004; 92 (06) 1320-1326
    PubMedGoogle Scholar
  • 76 Sánchez-Luceros A, Meschengieser SS, Marchese C. et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14 (07) 647-651
    CrossrefPubMedGoogle Scholar
  • 77 Perez Botero J, Reese JA, George JN, McIntosh JJ. Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: a guide for the consulting hematologist. Am J Hematol 2021; 96 (12) 1655-1665
    CrossrefPubMedGoogle Scholar
  • 78 Pillai VG, Bao J, Zander CB. et al. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood 2016; 128 (01) 110-119
    CrossrefPubMedGoogle Scholar
  • 79 Wang Y, Chen J, Ling M, López JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem 2015; 290 (03) 1422-1431
    CrossrefPubMedGoogle Scholar
  • 80 Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, López JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood 2011; 118 (19) 5283-5291
    CrossrefPubMedGoogle Scholar
  • 81 Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205 (09) 2065-2074
    CrossrefPubMedGoogle Scholar
  • 82 Wang A, Liu F, Dong N. et al. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Thromb Res 2010; 126 (04) e260-e265
    CrossrefPubMedGoogle Scholar
  • 83 Reuken PA, Kussmann A, Kiehntopf M. et al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int 2015; 35 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 84 Nguyen TC, Liu A, Liu L. et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92 (01) 121-124
    CrossrefPubMedGoogle Scholar
  • 85 Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105 (03) 1085-1093
    CrossrefPubMedGoogle Scholar
  • 86 Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra large von Willebrand factor multimers under flow. Blood 2004; 104 (01) 100-106
    CrossrefPubMedGoogle Scholar
  • 87 Bockmeyer CL, Claus RA, Budde U. et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93 (01) 137-140
    CrossrefPubMedGoogle Scholar
  • 88 Singh K, Kwong AC, Madarati H. et al. Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients. PLoS One 2021; 16 (02) e0247017
    CrossrefPubMedGoogle Scholar
  • 89 Shim CY, Liu YN, Atkinson T. et al. Molecular imaging of platelet-endothelial interactions and endothelial von Willebrand factor in early and mid-stage atherosclerosis. Circ Cardiovasc Imaging 2015; 8 (07) e002765
    CrossrefPubMedGoogle Scholar
  • 90 Xu H, Cao Y, Yang X. et al. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. Blood 2017; 130 (01) 11-22
    CrossrefPubMedGoogle Scholar
  • 91 Urashima S, Tsutsumi M, Nakase K, Wang JS, Takada A. Studies on capillarization of the hepatic sinusoids in alcoholic liver disease. Alcohol Alcohol Suppl 1993; 1B: 77-84
    CrossrefPubMedGoogle Scholar
  • 92 Albornoz L, Alvarez D, Otaso JC. et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30 (03) 451-455
    CrossrefPubMedGoogle Scholar
  • 93 Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Determination of ADAMTS13 and its clinical significance for ADAMTS13 supplementation therapy to improve the survival of patients with decompensated liver cirrhosis. Int J Hepatol 2011; 2011: 759047
    CrossrefPubMedGoogle Scholar
  • 94 Fukui S, Gutch S, Fukui S, Chu L, Wagner DD. Anti-inflammatory protective effect of ADAMTS-13 in murine arthritis models. J Thromb Haemost 2022; 20 (10) 2386-2393
    CrossrefPubMedGoogle Scholar
  • 95 Zhao BQ, Chauhan AK, Canault M. et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114 (15) 3329-3334
    CrossrefPubMedGoogle Scholar
  • 96 South K, Luken BM, Crawley JT. et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A 2014; 111 (52) 18578-18583
    CrossrefPubMedGoogle Scholar
  • 97 South K, Denorme F, Salles-Crawley II, De Meyer SF, Lane DA. Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke. J Thromb Haemost 2018; 16 (11) 2289-2299
    CrossrefPubMedGoogle Scholar
  • 98 Jain N, Marquez C, Martell L. Recombinant ADAMTS13 for patients with severe congenital thrombotic thrombocytopenic purpura: design of a phase 3b open-label continuation study of prophylactic and on-demand treatment. Blood 2021; 138 (01) 4252
    CrossrefPubMedGoogle Scholar
  • 99 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 100 Ward SE, Curley GF, Lavin M. et al; Irish COVID-19 Vasculopathy Study (ICVS) Investigators. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol 2021; 192 (04) 714-719
    CrossrefPubMedGoogle Scholar
  • 101 Grandone E, Vimercati A, Sorrentino F. et al. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis. BMC Pregnancy Childbirth 2022; 22 (01) 142
    CrossrefPubMedGoogle Scholar
  • 102 Maayan H, Kirgner I, Gutwein O. et al. Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine. J Thromb Haemost 2021; 19 (09) 2314-2317
    CrossrefPubMedGoogle Scholar
  • 103 de Bruijn S, Maes MB, De Waele L, Vanhoorelbeke K, Gadisseur A. First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost 2021; 19 (08) 2014-2018
    CrossrefPubMedGoogle Scholar
  • 104 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedGoogle Scholar
  • 105 Dykes KC, Kessler CM. First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2022; 33 (01) 71-73
    CrossrefPubMedGoogle Scholar
  • 106 Hamada E, Sakai K, Yamada S, Kubo M, Hayakawa M, Matsumoto M. No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey. Ann Hematol 2022; 101 (05) 1115-1117
    CrossrefPubMedGoogle Scholar
  • 107 Dos Santos C, Chavarri A, Alberto MF, Fondevila CG, Sánchez-Luceros A. Recurrence of atypical hemolytic uremic syndrome after COVID-19 vaccination. [abstract]. Can J Kidney Health Dis 2022: 9:6. Accessed August 21, 2022 at: https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1707163
    PubMedGoogle Scholar
  • 108 Dias PJ, Gopal S. Refractory thrombotic thrombocytopenic purpura following influenza vaccination. Anaesthesia 2009; 64 (04) 444-446
    CrossrefPubMedGoogle Scholar
  • 109 Kojima Y, Ohashi H, Nakamura T. et al. Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination. Blood Coagul Fibrinolysis 2014; 25 (05) 512-514
    CrossrefPubMedGoogle Scholar
  • 110 Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Centers for Disease Control and Prevention; 2021
    PubMedGoogle Scholar
  • 111 FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review. U.S. Food and Drug Administration (FDA); 2021
    Google Scholar
  • 112 Guo R, Yang J, Liu X, Wu J, Chen Y. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer. J Clin Lab Anal 2018; 32 (01) e22219
    CrossrefPubMedGoogle Scholar
  • 113 Bauer AT, Suckau J, Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood 2015; 125 (20) 3153-3163
    CrossrefPubMedGoogle Scholar
  • 114 Yang AJ, Wang M, Wang Y. et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis 2018; 7 (01) 12
    CrossrefPubMedGoogle Scholar
  • 115 Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res 2007; 120 (Suppl. 02) S64-S70
    CrossrefPubMedGoogle Scholar
  • 116 Weinberg RS, Grecco MO, Ferro GS. et al. A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Springerplus 2015; 4: 428-435
    CrossrefPubMedGoogle Scholar
  • 117 Pépin M, Kleinjan A, Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost 2016; 14 (02) 306-315
    CrossrefPubMedGoogle Scholar
  • 118 Liu C, Zhao L, Zhao J, Xu Q, Song Y, Wang H. Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients. Medicine (Baltimore) 2017; 96 (07) e6136
    CrossrefPubMedGoogle Scholar
  • 119 Colonne CK, Favaloro EJ, Pasalic L. The intriguing connections between von Willebrand factor, ADAMTS13 and cancer. Healthcare (Basel) 2022; 10 (03) 557
    CrossrefPubMedGoogle Scholar
  • 120 Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22 (4, Suppl A): 6A-13A
    CrossrefPubMedGoogle Scholar
  • 121 Reichman-Warmusz E, Brzozowa-Zasada M, Wojciechowska C, Dudek D, Warmusz O, Wojnicz R. Decreased immunoreactivity of von Willebrand factor may reflect persistent nature of the endothelial dysfunction in non-ischemic heart failure. Folia Histochem Cytobiol 2021; 59 (02) 108-113
    CrossrefPubMedGoogle Scholar
  • 122 Corban MT, Godo S, Burczak DR. et al. Coronary endothelial dysfunction is associated with increased risk of incident atrial fibrillation. J Am Heart Assoc 2020; 9 (08) e014850
    CrossrefPubMedGoogle Scholar
  • 123 Al-Masri AA, Habib SS, Hersi A, Al Zamil H. Effect of acute myocardial infarction on a disintegrin and metalloprotease with thrombospondin motif 13 and von Willebrand factor and their relationship with markers of inflammation. Int J Vasc Med 2020; 2020: 4981092
    PubMedGoogle Scholar
  • 124 Bongers TN, de Bruijne EL, Dippel DW. et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207 (01) 250-254
    CrossrefPubMedGoogle Scholar
  • 125 Gombos T, Makó V, Cervenak L. et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102 (03) 573-580
    Article in Thieme ConnectPubMedGoogle Scholar
  • 126 Reardon B, Pasalic L, Favaloro EJ. The intriguing relationships of von Willebrand factor, ADAMTS13 and cardiac disease. J Cardiovasc Dev Dis 2021; 8 (09) 115
    CrossrefPubMedGoogle Scholar
  • 127 Lazzari MA, Sanchez-Luceros A, Woods AI, Alberto MF, Meschengieser SS. Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis. Hematology 2012; 17 (Suppl. 01) S150-S152
    CrossrefPubMedGoogle Scholar